JP2023543978A5 - - Google Patents
Info
- Publication number
- JP2023543978A5 JP2023543978A5 JP2023516587A JP2023516587A JP2023543978A5 JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5 JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023516587 A JP2023516587 A JP 2023516587A JP 2023543978 A5 JP2023543978 A5 JP 2023543978A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antagonist
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078485P | 2020-09-15 | 2020-09-15 | |
| US63/078,485 | 2020-09-15 | ||
| PCT/US2021/050143 WO2022060678A1 (en) | 2020-09-15 | 2021-09-14 | Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543978A JP2023543978A (ja) | 2023-10-19 |
| JP2023543978A5 true JP2023543978A5 (https=) | 2024-09-25 |
Family
ID=80777346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516587A Pending JP2023543978A (ja) | 2020-09-15 | 2021-09-14 | がん患者を治療するためのｐｄ－１拮抗薬及びｌａｇ３拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240010729A1 (https=) |
| EP (1) | EP4213846A4 (https=) |
| JP (1) | JP2023543978A (https=) |
| KR (1) | KR20230069957A (https=) |
| CN (1) | CN116457016A (https=) |
| AU (1) | AU2021344849A1 (https=) |
| CA (1) | CA3195058A1 (https=) |
| MX (1) | MX2023003032A (https=) |
| WO (1) | WO2022060678A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064794A1 (en) * | 2021-08-10 | 2025-02-27 | Eisai R&D Management Co., Ltd. | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
| TW202509063A (zh) * | 2023-08-21 | 2025-03-01 | 瑞士商百濟神州瑞士有限責任公司 | 用抗lag3、抗pd-1和化學療法治療食管癌 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| WO2017079746A2 (en) * | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US11045547B2 (en) * | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| EP3793557A1 (en) * | 2018-05-14 | 2021-03-24 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| CN112839652A (zh) * | 2018-08-15 | 2021-05-25 | 艾葳生物科技有限公司 | VEGF和TGFβ的多激酶抑制剂及其用途 |
| EP3880709A4 (en) * | 2018-11-05 | 2022-07-27 | Merck Sharp & Dohme Corp. | DOSING REGIME OF ANTI-LAG3 ANTIBODIES AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER |
| EP3876990A4 (en) * | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
-
2021
- 2021-09-14 AU AU2021344849A patent/AU2021344849A1/en not_active Abandoned
- 2021-09-14 EP EP21870037.5A patent/EP4213846A4/en not_active Withdrawn
- 2021-09-14 US US18/245,222 patent/US20240010729A1/en active Pending
- 2021-09-14 CA CA3195058A patent/CA3195058A1/en active Pending
- 2021-09-14 MX MX2023003032A patent/MX2023003032A/es unknown
- 2021-09-14 KR KR1020237012134A patent/KR20230069957A/ko active Pending
- 2021-09-14 WO PCT/US2021/050143 patent/WO2022060678A1/en not_active Ceased
- 2021-09-14 CN CN202180076962.3A patent/CN116457016A/zh active Pending
- 2021-09-14 JP JP2023516587A patent/JP2023543978A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501162A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| JP2018070648A5 (https=) | ||
| JP2020516240A5 (https=) | ||
| JP2017507900A5 (https=) | ||
| JP2021513540A5 (https=) | ||
| JP2017514795A5 (https=) | ||
| JP2020503273A5 (https=) | ||
| JP2017533912A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| JP2020504141A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| JP2018516966A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2017514461A5 (https=) | ||
| JP2018527383A5 (https=) | ||
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2022500410A5 (https=) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2022512750A5 (https=) | ||
| JP2025092589A5 (https=) |